The test combines two previously CE marked assays that are based on the company's Nucleosomics platform for identifying and quantifying nucleosome structural features.
The company is working with DKFZ to evaluate its NuQ test, which can identify chromosome fragments circulating in blood and analyze them for epigenetic modifications.
The tests are based on the company's Nucleosomics platform for identifying and quantifying nucleosome structural features such as histone modifications.
The blood-based assay, which uses the company's nucleosome detection technology, is the first of several that will be bundled together as a test for cancer diagnosis.
The study will evaluate the ability of VolitionRx's technology to detect prostate cancer and to distinguish different prostate conditions and healthy samples.
The firm closed its offering of 2,475,000 shares of stock at a price of $3.75 per share. It plans to use the proceeds to fund colorectal cancer clinical trials.
